Edition:
United Kingdom

People: WAVE Life Sciences Ltd (WVE.OQ)

WVE.OQ on NASDAQ Stock Exchange Global Market

40.25USD
16 Nov 2018
Change (% chg)

$1.39 (+3.58%)
Prev Close
$38.86
Open
$38.85
Day's High
$40.43
Day's Low
$38.85
Volume
91,732
Avg. Vol
40,866
52-wk High
$56.00
52-wk Low
$27.25

Regnante, Keith 

Mr. Keith Regnante is the Chief Financial Officer since August 2016. Prior to joining us, from February 2014 to August 2016, Mr. Regnante served as Vice President of Finance at Shire Pharmaceuticals, a global biopharmaceutical company. Mr. Regnante also served on the Financial Leadership Team and the R&D Leadership Team while he was at Shire. From September 2013 to February 2014, he served as Head of R&D Finance for ARIAD Pharmaceuticals, Inc. From January 1999 to August 2013, Mr. Regnante held multiple positions within finance for Biogen Inc., including Senior Director of Corporate Finance from 2011 to 2013, Senior Director of Worldwide R&D Finance from 2008 to 2011, and several other positions dating back to 1999. Prior to joining finance organizations for biotechnology companies, Mr. Regnante worked as a consultant at The Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.

Basic Compensation

Total Annual Compensation, USD 120,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,519,220
Fiscal Year Total, USD 1,639,220

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gregory Verdine

282,127

Paul Bolno

3,196,640

Keith Regnante

1,639,220

Christopher Francis

1,103,510

Chandra Vargeese

1,157,260

Michael Panzara

2,762,040
As Of  31 Dec 2017